NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Myoforte Therapeutics, Inc.

Myoforte Therapeutics, Inc.

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://www.myoforte.com/

Last Round

Corporate Funding

Dec 1, 2024

Total Funding Raised

$85M

Company Overview

Myoforte Therapeutics, Inc. is a biopharmaceutical company that develops small molecule drugs designed to enhance muscle regeneration and strength by targeting muscle stem cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicinePGDH inhibitormuscle-wasting diseaseDuchenne muscular dystrophyDMDsarcopeniasmall molecule drugsmuscle atrophybiotechdrug discoverymuscle regenerationbiopharmaclinical-stage biotechtherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Myoforte Therapeutics, Inc. Comparables

Compare Myoforte Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Myoforte Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Epirium Bio
90%
Sarcomatrix Therapeutics Corp.
85%
Rejuvenate Biomed
81%

Myoforte Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingDec 1, 2024
Series ADec 18, 2019

Myoforte Therapeutics, Inc. Investors

Notable investors and investment history

Myoforte Therapeutics, Inc. investors
InvestorRounds
Longitude CapitalSeries A, Corporate Funding
Vertex Ventures HCSeries A, Corporate Funding
ARCH Venture PartnersSeries A, Corporate Funding
Bluebird VenturesSeries A, Corporate Funding
The Longevity FundSeries A, Corporate Funding
Adams Street PartnersSeries A, Corporate Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 1, 2024

    Raised corporate funding from ARCH Venture Partners and others.

  • Dec 18, 2019

    $85M round with ARCH Venture Partners and Bluebird Ventures.

Myoforte Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Myoforte Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Myoforte Therapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range1
Year Founded2017
Last FundingDec 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.